INO · Inovio Pharmaceuticals Inc
United States · RS rating 14 · As of 2026-10-14
| Price | 0.99 USD |
|---|---|
| 1-day change | -1.4% |
| RS rating (overall / 1M / 3M / 12M) | 14 / 16 / 29 / 11 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 25 / 13 / 37 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +75.0% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +62.1% |
| Market cap (USD) | $93.0M |